Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine in Midlife MDD Imaging Study
NCT00888862Phase 3Unknown
- Sponsor
- Hamilton Health Sciences
- Start
- Jun 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD), sponsored by Hamilton Health Sciences. Primary endpoint: Effects of desvenlafaxine succinate (DVS) on brain structure and activation in midlife men and women with MDD at 10 weeks. Status: unknown.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00888862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888862.